
TALTZ ® is a humanized interleukin-17A antagonist indicated for the treatment of:
TALTZ ® is indicated for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
TALTZ is indicated for the treatment of adult patients with active psoriatic arthritis.
TALTZ is indicated for the treatment of adult patients with active ankylosing spondylitis.
TALTZ is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.